Skip to content
10-Q

Quarterly Report

NEUMORA THERAPEUTICS, INC. NMRA

0001193125-26-211825

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 185.28M sh
Shares Diluted Q1 2026 · Mar 31, 2026 179.87M sh
Shares Diluted Q1 2026 · Mar 31, 2025 161.45M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$46.4M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$59.45M
Long Term Debt Q1 2026 · Mar 31, 2026 $52.96M
Long Term Debt Q1 2026 · Dec 31, 2025 $54.53M
Short Term Debt Q1 2026 · Mar 31, 2026 $60M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $147.07M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $182.53M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $126.86M
Stockholders Equity Q1 2026 · Mar 31, 2026 $70.68M
Stockholders Equity Q1 2026 · Dec 31, 2025 $103.87M
Stockholders Equity Q1 2026 · Mar 31, 2025 $228.36M
Stockholders Equity Q1 2026 · Dec 31, 2024 $287.06M
Current Liabilities Q1 2026 · Mar 31, 2026 $30.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $32.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $83.2M
Total Liabilities Q1 2026 · Dec 31, 2025 $87.18M
Current Assets Q1 2026 · Mar 31, 2026 $153.43M
Current Assets Q1 2026 · Dec 31, 2025 $190.54M
Total Assets Q1 2026 · Mar 31, 2026 $153.88M
Total Assets Q1 2026 · Dec 31, 2025 $191.05M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.30
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.30
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $14.27M
Sga Expense Q1 2026 · Mar 31, 2025 $18.79M
Rd Expense Q1 2026 · Mar 31, 2026 $38.6M
Rd Expense Q1 2026 · Mar 31, 2025 $52.15M
Net Income Q1 2026 · Mar 31, 2026 −$53.46M
Net Income Q1 2026 · Mar 31, 2025 −$67.99M
Operating Income Q1 2026 · Mar 31, 2026 −$52.86M
Operating Income Q1 2026 · Mar 31, 2025 −$70.94M